Drug Profile
Astegolimab - Genentech
Alternative Names: AMG-282; Anti-ST2; MSTT 1041 A; RG 6149; RO 7187807; ST2 MAbLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; Genentech; Roche; University of Leicester
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-33 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic obstructive pulmonary disease
- Phase II Allergic asthma; Atopic dermatitis
- Discontinued Asthma; COVID-19 pneumonia; Rhinosinusitis
Most Recent Events
- 09 Sep 2023 Updated efficacy data from a phase II trial in Chronic obstructive pulmonary disease presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 28 Jun 2023 Roche initiates a phase III trial for Chronic obstructive pulmonary disease in USA (SC) (NCT05878769)
- 21 Jun 2023 Roche plans to submit regulatory fillings in Chronic obstructive pulmonary disease, in or after 2026 (Roche pipeline, June 2023)